Xinlay Access Program Canceled

[Guest guest]

From NPCC's aware

Xinlay Access Program Canceledby Antonia Scatton | NPCC | 12.05.2005

Abbott has discontinued the expanded access program (EAP) for its experimental drug XinlayTM (atrasentan) after conversations with the FDA, which turned down Abbott's request for the drug's approval at a hearing in September. Abbott had been seeking approval for the treatment of men with advanced prostate cancer metastasized to the bone, but failed to conclusively demonstrate reduction in the spread of bone metastasis.

XinlayTM will still be available to patients on an individual basis, although the process for gaining access will begin with a patient's physician and require the physician to file a request with the FDA and Abbott.

http://tinyurl.com/a4jvl

Kathy Meade

Arlington Educational Consulting

http://www.vapcacoalition.org/

http://www.naspcc.org/

phone

fax

The truth is that our finest moments are most likely to occur when we are feeling deeply uncomfortable, unhappy, or unfulfilled. For it is only in such moments, propelled by our discomfort, that we are likely to step out of our ruts and start searching for different ways or truer answers.

M. Peck